|
Post by peppy on Aug 16, 2019 11:09:59 GMT -5
September 05, 2018 07:00 AM Eastern Daylight Time LOS ANGELES--(BUSINESS WIRE)--Westlake Village BioPartners, a new venture firm exclusively focused on investing in life sciences, announced the launch of the firm’s first fund with $320 million of committed capital. The founding team will include industry veterans and managing directors, Beth Seidenberg, M.D. – general partner at Kleiner Perkins and former chief medical officer and head of global development at Amgen – and Sean Harper, M.D., executive vice president and head of R&D at Amgen who will move to the firm in January 2019. Dr. Seidenberg and Dr. Harper will lead Westlake’s investing activities. Scott Ryles, chief operating officer at Kleiner Perkins, will be Westlake’s chief operating officer. The Westlake approach is distinctive and based on Dr. Seidenberg’s successful track record in venture investing. The firm will invest in early-stage opportunities and incubating companies, matching the best entrepreneurial talent with promising, carefully-selected technologies from academia, companies, or de novo assets with breakthrough potential. Westlake will also make select investments in later-stage companies, creating a diversified portfolio. www.businesswire.com/news/home/20180905005261/en/Westlake-Village-BioPartners-Unveils-320-Million-Inaugural======================================================================================================= 1. They know the product is superior, they can see that on continuous glucose monitors. (Up periscope) www.screencast.com/t/kk8dZJGYktG2. who ever ends up with MNKD ends up with its patents. Remember UTHR? 3. have you seen the interest rates on the US treasuries? Hard to made money in bonds. 4. Remember Kleiner Perkins, first deal at 6?, the second at ridiculously low as their investors were furious? Am I remembering correctly? 5. All they have to do is prove it for the label? Get better treatment on the ADA protocol? The public proof so far has hardly been able to move the health insurance coverage business needle. The ADA is however adding guidelines/starting to use Continuous Glucose Monitoring.
|
|
|
Post by audiomr on Aug 16, 2019 11:18:44 GMT -5
September 05, 2018 07:00 AM Eastern Daylight Time LOS ANGELES--(BUSINESS WIRE)--Westlake Village BioPartners, a new venture firm exclusively focused on investing in life sciences, announced the launch of the firm’s first fund with $320 million of committed capital. The founding team will include industry veterans and managing directors, Beth Seidenberg, M.D. – general partner at Kleiner Perkins and former chief medical officer and head of global development at Amgen – and Sean Harper, M.D., executive vice president and head of R&D at Amgen who will move to the firm in January 2019. Dr. Seidenberg and Dr. Harper will lead Westlake’s investing activities. Scott Ryles, chief operating officer at Kleiner Perkins, will be Westlake’s chief operating officer. The Westlake approach is distinctive and based on Dr. Seidenberg’s successful track record in venture investing. The firm will invest in early-stage opportunities and incubating companies, matching the best entrepreneurial talent with promising, carefully-selected technologies from academia, companies, or de novo assets with breakthrough potential. Westlake will also make select investments in later-stage companies, creating a diversified portfolio. www.businesswire.com/news/home/20180905005261/en/Westlake-Village-BioPartners-Unveils-320-Million-Inaugural======================================================================================================= 1. They know the product is superior, they can see that on continuous glucose monitors. (Up periscope) www.screencast.com/t/kk8dZJGYktG2. who ever ends up with MNKD ends up with its patents. Remember UTHR? 3. have you seen the interest rates on the US treasuries? Hard to made money in bonds. 4. Remember Kleiner Perkins, first deal at 6?, the second at ridiculously low as their investors were furious? Am I remembering correctly? 5. All they have to do is prove it for the label? Get better treatment on the ADA protocol? The public proof so far has hardly been able to move the health insurance coverage business needle. The ADA is however adding guidelines/starting to use Continuous Glucose Monitoring. 3. Good money to be made in corporate bonds, though.
|
|
|
Post by awesomo on Aug 16, 2019 11:20:10 GMT -5
MannKind is neither an early-stage company nor a potential company for an incubator. VC money is thrown at the hot new startups looking to hit a HR.
|
|
|
Post by peppy on Aug 16, 2019 11:24:46 GMT -5
MannKind is neither an early-stage company nor a potential company for an incubator. VC money is thrown at the hot new startups looking to hit a HR. have you met Tinkerbell? MNKD IS a hot new start up.
|
|
|
Post by hellodolly on Aug 16, 2019 13:46:06 GMT -5
Mike mentioned on last weeks CC they are planning more partnerships to get the message out. So this is right up his ally. Partnering to promote LA as a biotechnology center doesn't strike me as particularly beneficial to either Mannkind or afrezza. Tell us, what does it 'strike you' as if not beneficial? Some greta SMEs in the industry come together to collaborate and speak about the LA area as a biotech center. Surely, it must have some benefit. I'd like to get your version.
|
|
|
Post by sayhey24 on Aug 16, 2019 16:11:43 GMT -5
I think it is awesome Mike is talking with his old AMGN friends. Who knows what could happen. Everyone here knows how huge afrezza will be. How long did it take Spencer Silver to find Art Fry? Just like Mike gets laughed at so did Spencer Silver.
Mike just needs his own Art Fry to take afrezza to the level Al Mann predicted, "the greatest selling drug of all time"
|
|
|
Post by careful2invest on Aug 16, 2019 17:04:34 GMT -5
MannKind is neither an early-stage company nor a potential company for an incubator. VC money is thrown at the hot new startups looking to hit a HR. So very surprising of you to post a negative sentiment shooting down a potential positive about MNKD or Afrezza... shocking!!
|
|
|
Post by awesomo on Aug 16, 2019 17:10:56 GMT -5
MannKind is neither an early-stage company nor a potential company for an incubator. VC money is thrown at the hot new startups looking to hit a HR. So very surprising of you to post a negative sentiment shooting down a potential positive about MNKD or Afrezza... shocking!! Sorry that reality isn't all roses, but hey, keep living in your fantasy world... VCs aren't touching MannKind.
|
|
|
Post by careful2invest on Aug 16, 2019 17:18:23 GMT -5
So very surprising of you to post a negative sentiment shooting down a potential positive about MNKD or Afrezza... shocking!! Sorry that reality isn't all roses, but hey, keep living in your fantasy world... VCs aren't touching MannKind. As a nearly 10 year long, well into six figure losses (on paper) with my investment in MNKD, I am more than familiar with reality, as well as lack of roses! So I must ask... How do YOU know for a fact that Westlake Village has no interest in any way shape or form in Afrezza or in MNKD? Please enlighten us with your clairvoyant wisdom.
|
|
|
Post by awesomo on Aug 16, 2019 17:25:05 GMT -5
I already said venture capital firms have no interest in public companies that are in financial distress with a product that has been on the market for 5 years. Venture capital firms are looking for potential unicorn private companies (over $1B valuation) that can have huge IPOs, so the next Uber, AirBnB, or even Moderna.
|
|
|
Post by careful2invest on Aug 16, 2019 17:30:24 GMT -5
I already said venture capital firms have no interest in public companies that are in financial distress with a product that has been on the market for 5 years. Venture capital firms are looking for potential unicorn private companies (over $1B valuation) that can have huge IPOs, so the next Uber, AirBnB, or even Moderna. Time will tell...
|
|
|
Post by agedhippie on Aug 16, 2019 17:40:03 GMT -5
I already said venture capital firms have no interest in public companies that are in financial distress with a product that has been on the market for 5 years. Venture capital firms are looking for potential unicorn private companies (over $1B valuation) that can have huge IPOs, so the next Uber, AirBnB, or even Moderna. Time will tell... Indeed. I think for a VC to take a position in a long established company like Mannkind would be extremely unlikely. You might get PE though, but I suspect they would dump Afrezza and keep the Technosphere side.
|
|
|
Post by awesomo on Aug 16, 2019 17:49:28 GMT -5
Indeed. I think for a VC to take a position in a long established company like Mannkind would be extremely unlikely. You might get PE though, but I suspect they would dump Afrezza and keep the Technosphere side. Private Equity is a much more realistic scenario, though I doubt any long term shareholders would like this route much.
|
|
|
Post by nylefty on Aug 16, 2019 18:20:55 GMT -5
I already said venture capital firms have no interest in public companies that are in financial distress with a product that has been on the market for 5 years. Venture capital firms are looking for potential unicorn private companies (over $1B valuation) that can have huge IPOs, so the next Uber, AirBnB, or even Moderna. Speaking of Uber.. www.forbes.com/sites/greatspeculations/2019/08/16/uber-gives-investors-the-worst-of-both-worlds/#21a719ec36b0From the article: I'm not going to talk about Uber’s losses here, even though the amount of money the company loses (its operating cash flow was -$1.6 billion in Q2) is astonishing. Everyone knows Uber loses money. At this point, the amount of money you’re able to lose seems to be a point of pride in Silicon Valley.
|
|
|
Post by awesomo on Aug 16, 2019 18:33:13 GMT -5
I already said venture capital firms have no interest in public companies that are in financial distress with a product that has been on the market for 5 years. Venture capital firms are looking for potential unicorn private companies (over $1B valuation) that can have huge IPOs, so the next Uber, AirBnB, or even Moderna. Uber? www.forbes.com/sites/greatspeculations/2019/08/16/uber-gives-investors-the-worst-of-both-worlds/#21a719ec36b0From the article: I'm not going to talk about Uber’s losses here, even though the amount of money the company loses (its operating cash flow was -$1.6 billion in Q2) is astonishing. Everyone knows Uber loses money. At this point, the amount of money you’re able to lose seems to be a point of pride in Silicon Valley.Umm, Uber's current valuation (whether warranted or not) is $60 billion. Any VC firm involved with Uber made an absolute boatload of money and have probably already cashed out. They couldn't care less about the current operating losses. American early-stage VC Benchmark set to make 750x return on the $9 million they had invested in Uber in 2011
|
|